RxDoctor Payments DataLook up a doctor →

David Homan, MD

Interventional Cardiology · Opelousas, LANPI 1164681334

Payments from drug & device makers

$90,125in general payments, 2019–2025

Across 500 payments — averaging $180.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kiniksa Pharmaceuticals International, PLC$55K
  • Kiniksa Pharmaceuticals, Ltd.$17K
  • Angiodynamics, Inc.$7K
  • Boston Scientific$1K
  • Abiomed$857
  • Inari Medical, Inc.$777
  • plus $8K from 45 others

What the payments were for

  • Consulting fees$2,9003%
  • Speaking & faculty fees$58,95065%
  • Grants$160%
  • Travel & lodging$9,53411%
  • Food & beverage$12,16213%
  • Education$1830%
  • Other$6,3807%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$90,125 in reported general payments places this provider in the 80th percentile of 171 interventional cardiology providers in Louisiana.

See all interventional cardiology providers in Louisiana

Medicare billing

Part B allowed, 2024
$462,269
Medicare patients
1,081
Services billed
6,570

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban685$519,502
EntrestoSacubitril/Valsartan337$272,197
XareltoRivaroxaban315$214,517
Repatha SureclickEvolocumab123$79,392
OzempicSemaglutide42$49,457
FarxigaDapagliflozin Propanediol77$48,426
WegovySemaglutide28$38,071
Praluent PenAlirocumab68$37,767
NexletolBempedoic Acid58$29,969
NexlizetBempedoic Acid/Ezetimibe30$18,572
Atorvastatin Calcium2,421$18,175
VascepaIcosapent Ethyl45$16,449
Repatha SyringeEvolocumab18$12,908
JardianceEmpagliflozin16$12,671
Metoprolol Succinate1,265$11,775

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$746$519,502685 claims
NovartisEntresto$632$272,197337 claims
Johnson & JohnsonXarelto$297$214,517315 claims
Novo NordiskOzempic, Wegovy$608$87,52870 claims
Esperion Therapeutics, Inc.Nexletol, Nexlizet$55$48,54188 claims
AstraZenecaFarxiga$67$48,42677 claims
Boehringer IngelheimJardiance$20$12,67116 claims
MerckVerquvo$33$8,24412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 171 interventional cardiology providers in Louisiana.

Other interventional cardiology in Opelousas

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →